Metabolic Complications of HIV and Antiretroviral Therapy: Dyslipidemia, Insulin Resistance, and Cardiovascular Disease
Summary
- Patients on lipid-lowering therapy should have fasting lipids monitored 6-12 weeks after therapy initiation and at similar intervals following dose increases
- Once stable, monitor every 6-12 months
- Use of support staff such as nutrition counselors or dieticians may be helpful
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content